

Treatment Clinical Trials Open to Enrollment at UMC Cancer Center

### **Breast – Medical**

**Protocol A011401** – Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer – [A011401 Trial](#)

**Protocol A011502** – A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive Her2 Negative Breast Cancer: The ABC Trial – [A011502 Study](#)

**Protocol S1501** – Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer – [S1501 Study](#)

### **Breast – Surgical**

**Protocol A011202:** A Randomized, Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-2, N1) Who have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy - [A011202 Trial](#)

### **Breast – Surgical/Radiation**

**NSABP B 51/RTOG1305**– A Randomized, Phase III Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before NAC Who Convert to Pathologically Negative Axillary Nodes after Neoadjuvant Chemotherapy - [B-51 Trial](#)

### **Lung – Non-Small Cell Lung Cancer**

**Protocol CA209-816** - Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC – CheckMate 816 - [CA209-816](#)

## **Acute Myeloid Leukemia (AML)**

**MB-104** – Phase 1/2 Study of Liposomal Annamycin for the Treatment of Subjects with Acute Myeloid Leukemia (AML) that is Refractory to or Relapsed after Standard Induction Therapy [MB-104](#)

## **Diffuse Large B-Cell Lymphoma**

**Protocol #MOR00208C204 – Morphosys B-MIND Study** – A Phase II/III, Randomized, Multicenter Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem –Cell Transplantation (ASCT) – [B-MIND Study](#)

## **Solid Tumors and Non-Hodgkin's Lymphoma**

**SPOC-2010-002** – Phase I Trial of Intravenous Fenretinide (4-HPR) plus Intravenous Safingol for Patients with Relapsed Malignancies - [SPOC Phase I](#)